Age at Diagnosis and Prognosis in Children With Neuroblastoma
Author:
Affiliation:
1. The University of Pennsylvania School of Medicine, and The Children's Hospital of Philadelphia, Philadelphia, PA
Publisher
American Society of Clinical Oncology (ASCO)
Subject
Cancer Research,Oncology
Link
http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2005.05.005
Reference12 articles.
1. Evidence for an Age Cutoff Greater Than 365 Days for Neuroblastoma Risk Group Stratification in the Children's Oncology Group
2. Hyperdiploidy Plus Nonamplified MYCN Confers a Favorable Prognosis in Children 12 to 18 Months Old With Disseminated Neuroblastoma: A Pediatric Oncology Group Study
3. Favorable Prognosis for Patients 12 to 18 Months of Age With Stage 4 Nonamplified MYCN Neuroblastoma: A Children's Cancer Group Study
4. Wittenborg MH: Roentgen therapy in neuroblastoma: Review of 73 cases. Radiology 54:670,1950-688,
5. Everson TC, Cole WH . Spontaneous Regression of Cancer. Philadelphia, PA, WB Saunders, 1966
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Incidence, survival, and mortality of cancer in children and young adolescents in Belgium and the Netherlands in 2004–2015: A comparative population‐based study;International Journal of Cancer;2024-03-13
2. Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children's Oncology Group Risk Stratification;Journal of Clinical Oncology;2023-06-10
3. Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and withoutMYCNAmplification: A Children's Oncology Group (COG) Report;Clinical Cancer Research;2023-02-07
4. Radionuclide Therapy in Neuroectodermal Tumors;Radionuclide Therapy;2022
5. Clinical impact of primary tumour 123ImIBG response to induction chemotherapy in children with high-risk neuroblastoma;International Journal of Clinical Oncology;2021-10-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3